CR11061A - Derivados de piridina - Google Patents

Derivados de piridina

Info

Publication number
CR11061A
CR11061A CR11061A CR11061A CR11061A CR 11061 A CR11061 A CR 11061A CR 11061 A CR11061 A CR 11061A CR 11061 A CR11061 A CR 11061A CR 11061 A CR11061 A CR 11061A
Authority
CR
Costa Rica
Prior art keywords
compounds
preparation
piridine derivatives
piridine
derivatives
Prior art date
Application number
CR11061A
Other languages
English (en)
Inventor
Sharanjeet Kaur Bagal
Karl Richard Gibson
Mark Ian Kemp
Cedric Poinsard
Melanie Susanne Glossop
Blanda Luzia STAMMEN
Stephen Martin Denton
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CR11061A publication Critical patent/CR11061A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a compuestos de la formula (I): y sus sales y solvatos farmaceuticamente aceptables, a procedimientos para la preparacion de, intermedios usados en la preparacion de, y composiciones que contienen tales compuestos y los usos de tales compuestos para el tratamiento del dolor.
CR11061A 2007-05-03 2009-10-13 Derivados de piridina CR11061A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91574507P 2007-05-03 2007-05-03
US95753607P 2007-08-23 2007-08-23

Publications (1)

Publication Number Publication Date
CR11061A true CR11061A (es) 2009-11-03

Family

ID=39855225

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11061A CR11061A (es) 2007-05-03 2009-10-13 Derivados de piridina

Country Status (33)

Country Link
US (1) US8134007B2 (es)
EP (1) EP2183241B1 (es)
JP (1) JP4657384B2 (es)
KR (1) KR20100007956A (es)
CN (1) CN101675040A (es)
AP (1) AP2516A (es)
AR (1) AR070636A1 (es)
AU (1) AU2008247102B2 (es)
BR (1) BRPI0810202A2 (es)
CA (1) CA2684105C (es)
CL (1) CL2008001268A1 (es)
CO (1) CO6251367A2 (es)
CR (1) CR11061A (es)
CU (1) CU23846B1 (es)
DO (1) DOP2009000254A (es)
EA (1) EA015952B1 (es)
EC (1) ECSP099710A (es)
ES (1) ES2398606T3 (es)
GE (1) GEP20125379B (es)
GT (1) GT200900280A (es)
IL (1) IL201569A0 (es)
MA (1) MA31419B1 (es)
MX (1) MX2009011816A (es)
NI (1) NI200900192A (es)
NZ (1) NZ581614A (es)
PA (1) PA8779201A1 (es)
PE (1) PE20090730A1 (es)
SV (1) SV2009003400A (es)
TN (1) TN2009000450A1 (es)
TW (1) TWI375675B (es)
UY (1) UY31063A1 (es)
WO (1) WO2008135826A2 (es)
ZA (1) ZA200907609B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035295T2 (en) 2008-08-06 2018-05-02 Medivation Technologies Inc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
CA2747419C (en) 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
CN101638352B (zh) * 2009-08-14 2011-08-31 大连理工大学 一种芳基取代的氮杂环化合物的制备方法
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
CN101768036B (zh) * 2010-01-23 2013-05-08 大连理工大学 一种在醇溶剂中制备芳基取代的氮杂芳环化合物的方法
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
MX340319B (es) 2010-02-08 2016-07-06 Medivation Technologies Inc Procesos para sintetizar derivados de dihidropiridoftalazinona.
WO2011104649A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues
ES2526675T3 (es) 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
EP2593431B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
EP2593427B1 (en) 2010-07-12 2014-12-24 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP2593428B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
EP2630122B1 (en) * 2010-10-18 2016-11-30 RaQualia Pharma Inc Arylamide derivatives as ttx-s blockers
CN103282365B (zh) 2010-10-21 2017-12-29 麦迪韦逊科技有限公司 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
EP2694509B1 (en) 2011-04-05 2016-05-18 Pfizer Limited Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
WO2013008123A1 (en) 2011-07-13 2013-01-17 Pfizer Limited Enkephalin analogues
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
BR112014009102A2 (pt) 2011-10-26 2017-04-18 Pfizer Ltd compostos químicos
EP3243815B1 (en) 2011-10-28 2019-07-10 Inhibitaxin Limited Pyridazine derivatives useful in therapy
ES2593533T3 (es) 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
CA2860553C (en) 2012-01-04 2016-08-23 Pfizer Limited N-aminosulfonyl benzamides
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
IN2014MN01982A (es) * 2012-04-25 2015-07-10 Raqualia Pharma Inc
CA2885247A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Tropomyosin-related kinase inhibitors
JP2015531394A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤
CA2885259A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
CN104812755B (zh) * 2012-10-31 2017-08-08 拉夸里亚创药株式会社 作为ttx‑s阻断剂的吡唑并吡啶衍生物
EP2935257B1 (en) 2012-12-20 2018-02-07 Purdue Pharma LP Cyclic sulfonamides as sodium channel blockers
KR102226587B1 (ko) 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
CN105026373B (zh) * 2013-01-31 2018-03-30 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
EP2964644B1 (en) 2013-03-08 2018-12-26 Amgen, Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
JP6337109B2 (ja) 2013-07-19 2018-06-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤としてのスルホンアミド
CN105636952A (zh) 2013-10-15 2016-06-01 詹森药业有限公司 Rorγt的仲醇喹啉基调节剂
EP3066084A1 (en) * 2013-11-07 2016-09-14 Medivation Technologies, Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
SG11201604477SA (en) 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
CA2960274A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
CN106674264A (zh) * 2016-12-20 2017-05-17 苏州汉德创宏生化科技有限公司 (2,2,2‑三氟乙氧基)苯硼酸类化合物的合成方法
KR102714561B1 (ko) 2017-05-16 2024-10-10 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CN111163766A (zh) * 2017-08-17 2020-05-15 医肯纳肿瘤学公司 Ahr抑制剂和其用途
KR20200118005A (ko) * 2018-02-05 2020-10-14 위니베르시떼 드 스트라스부르 통증 치료용 화합물 및 조성물
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
CN109053434A (zh) * 2018-07-18 2018-12-21 上海华堇生物技术有限责任公司 一种2,4-二甲氧基苯甲酰氯的新制备方法
CN108794328A (zh) * 2018-08-03 2018-11-13 上海华堇生物技术有限责任公司 3,4-二甲氧基苯甲酰氯的制备方法
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
EP4010328A1 (en) 2019-08-06 2022-06-15 Domain Therapeutics 5-heteroaryl-pyridin-2-amine confounds as neuropeptide ff receptor antagonists
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN113248455A (zh) * 2021-05-25 2021-08-13 湖北科技学院 一种3,5-二取代异噁唑类衍生物及其合成方法
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
US20240368135A1 (en) 2021-06-04 2024-11-07 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
SMT202600064T1 (it) 2021-06-04 2026-03-09 Vertex Pharma Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
CN115703719B (zh) * 2021-08-03 2024-04-30 联化科技股份有限公司 一种溴化肟类化合物的制备方法
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
IL316422A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for pain treatment
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
KR20250120351A (ko) 2022-12-06 2025-08-08 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법
KR20260116141A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료용 화합물 및 이의 고체 형태의 제조방법
KR20260118418A (ko) 2023-10-23 2026-07-30 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
KR20260116140A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
AU2024393245A1 (en) 2023-12-07 2026-06-18 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
TW202606663A (zh) 2024-06-28 2026-02-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
LU605402B1 (en) 2024-07-11 2026-07-14 Sea4Us Biotecnologia E Recursos Marinhos Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
EP0674627A1 (en) 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
AU4515896A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
DE19857009A1 (de) 1998-12-10 2000-06-15 Aventis Pharma Gmbh Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren
US6458789B1 (en) 1999-09-29 2002-10-01 Lion Bioscience Ag 2-aminopyridine derivatives and combinatorial libraries thereof
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
NZ522990A (en) * 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
DE10132308A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Kombinationspräparat zur Therapie von immunologischen Erkrankungen
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
JP2003086564A (ja) * 2001-09-14 2003-03-20 Mitsubishi Electric Corp 遠心乾燥装置および半導体装置の製造方法ならびに半導体製造装置
AU2002363250A1 (en) * 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CN100369898C (zh) 2002-02-12 2008-02-20 史密丝克莱恩比彻姆公司 用作p38抑制剂的烟酰胺衍生物
WO2004080999A1 (en) 2003-03-14 2004-09-23 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
EP1625115A1 (en) 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Substituted pyrimidine derivatives
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
MXPA06003123A (es) 2003-09-22 2006-05-31 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
CA2555890A1 (en) 2004-03-02 2005-09-15 Neurogen Corporation Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues
WO2006011050A2 (en) * 2004-07-23 2006-02-02 Pfizer Limited Pyridine derivatives
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
US20060106011A1 (en) * 2004-11-12 2006-05-18 Bock Mark G 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation
CN101253152A (zh) 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
DK1928886T3 (da) 2005-09-09 2011-07-11 Glaxosmithkline Llc Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser
EP1764093A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel aromatic compounds and their use in medical applications
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
TW200732320A (en) 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
AU2006310367A1 (en) 2005-10-31 2007-05-10 Biolipox Ab Triazole compounds as lipoxygenase inhibitors
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
NL2000284C2 (nl) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
BRPI0619208A2 (pt) 2005-11-30 2011-09-20 Astellas Pharma Inc derivado de 2-aminobenzamida c07d 307/14 c07d 307/22 c07d 309/14 c07d 319/12 c07d 401/12 c07d 405/12 c07d 413/12 c07d 417/12
EP1984339A1 (en) 2006-01-23 2008-10-29 Pfizer Limited Pyridine derivatives as sodium channel modulators
JP2009528273A (ja) 2006-01-25 2009-08-06 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用用の置換ビアリール化合物
AU2007211276B2 (en) 2006-01-31 2013-06-06 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
AU2007216247A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as TLR7 modulators
PT2402319T (pt) 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US7795249B2 (en) 2006-12-22 2010-09-14 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
WO2008086014A2 (en) 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
US20100227872A1 (en) 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives

Also Published As

Publication number Publication date
US20090048306A1 (en) 2009-02-19
WO2008135826A2 (en) 2008-11-13
ECSP099710A (es) 2009-11-30
CL2008001268A1 (es) 2008-11-03
NZ581614A (en) 2011-06-30
MA31419B1 (fr) 2010-06-01
AU2008247102B2 (en) 2011-11-24
MX2009011816A (es) 2009-11-19
CN101675040A (zh) 2010-03-17
GEP20125379B (en) 2012-01-10
ZA200907609B (en) 2011-04-28
CU23846B1 (es) 2012-10-15
AP2516A (en) 2012-11-26
NI200900192A (es) 2010-07-15
EP2183241B1 (en) 2012-12-19
AU2008247102A1 (en) 2008-11-13
SV2009003400A (es) 2010-08-17
KR20100007956A (ko) 2010-01-22
PE20090730A1 (es) 2009-07-11
AP2009005009A0 (en) 2009-10-31
EA015952B1 (ru) 2011-12-30
WO2008135826A3 (en) 2009-02-05
EA200970913A1 (ru) 2010-04-30
EP2183241A2 (en) 2010-05-12
AR070636A1 (es) 2010-04-28
GT200900280A (es) 2011-08-29
TW200906403A (en) 2009-02-16
ES2398606T3 (es) 2013-03-20
CA2684105A1 (en) 2008-11-13
DOP2009000254A (es) 2009-11-30
CO6251367A2 (es) 2011-02-21
IL201569A0 (en) 2010-05-31
US8134007B2 (en) 2012-03-13
UY31063A1 (es) 2009-01-05
TWI375675B (en) 2012-11-01
TN2009000450A1 (fr) 2011-03-31
JP2010526050A (ja) 2010-07-29
CU20090180A7 (es) 2011-05-27
CA2684105C (en) 2011-09-06
BRPI0810202A2 (pt) 2014-10-21
PA8779201A1 (es) 2009-01-23
JP4657384B2 (ja) 2011-03-23

Similar Documents

Publication Publication Date Title
CU20090180A7 (es) Derivados de piridina
CO6400220A2 (es) Derivados de sulfonamida
CR8859A (es) Derivados de piridina
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
UY30804A1 (es) Derivados de nicotinamida, sus sales y solvatos, composiciones farmacéuticas conteniendolas y aplicaciones
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
ECSP099706A (es) Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2yl) y n-(5-heteroarilcroman-3-il) carboxamida para el tratamiento del dolor
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
PA8511801A1 (es) Derivados de purina
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
UY31639A1 (es) Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
UY33075A (es) Derivados de ciclohexano y usos de los mismos
UY31141A1 (es) Compuestos de piperidina y sus usos
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
UY30938A1 (es) Derivados de nicotinamida, sales y solvatos farmacéuticamente aceptables, composiciones y aplicaciones.
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
UY30933A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones farmacéuticas que contienen tales compuestos y aplicaciones.
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
UY31289A1 (es) Nuevos derivados de la quinoliniloxipiperidina y pirrolidina, su preparacion, composiciones farmaceuticas que los contiene y sus usos en el tratamieno de enfermedades

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)